Voxelwise Analysis of Diffusion Tensor Imaging and Structural MR Imaging in Patients with the m.3243A>G Mutation in Mitochondrial DNA

References

1. 1.↵
   1. DiMauro S,
   2. Schon EA

   . Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008;31:91–123

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Chinnery PF,
   2. Johnson MA,
   3. Wardell TM,
   4. et al

   . The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000;48:188–93

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Uusimaa J,
   2. Moilanen JS,
   3. Vainionpää L,
   4. et al

   . Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. Ann Neurol 2007;62:278–87

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Manwaring N,
   2. Jones MM,
   3. Wang JJ,
   4. et al

   . Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7:230–33

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Elliott HR,
   2. Samuels DC,
   3. Eden JA,
   4. et al

   . Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008;83:254–60

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Majamaa K,
   2. Moilanen JS,
   3. Uimonen S,
   4. et al

   . Epidemiology of A3234G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998;63:447–54

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Hirano M,
   2. Pavlakis SG

   . Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol 1994;9:4–13

   Abstract/FREE Full Text
8. 8.↵
   1. Tanahashi C,
   2. Nakayama A,
   3. Yoshida M,
   4. et al

   . MELAS with the mitochondrial DNA 3243 point mutation: a neuropathological study. Acta Neuropathol 2000;99:31–38

   CrossRefPubMed
9. 9.↵
   1. Yokoyama T,
   2. Hasegawa K,
   3. Obama R,
   4. et al

   . MELAS with diffuse degeneration of the white matter: report of an autopsy case. Neuropathology 2010;30:56–60

   CrossRefPubMed
10. 10.↵
    1. Majamaa-Voltti KA,
    2. Winqvist S,
    3. Remes AM,
    4. et al

    . A 3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA. Neurology 2006;66:1470–75

    Abstract/FREE Full Text
11. 11.↵
    1. Schapira AH

    . Mitochondrial disease. Lancet 2006;368:70–82

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Ducreux D,
    2. Nasser G,
    3. Lacroix C,
    4. et al

    . MR diffusion tensor imaging, fiber tracking, and single-voxel spectroscopy findings in an unusual MELAS case. AJNR Am J Neuroradiol 2005;26:1840–44

    Abstract/FREE Full Text
13. 13.↵
    1. Brockmann K,
    2. Finsterbusch J,
    3. Schara U,
    4. et al

    . Stroke-like pattern in DTI and MRS of childhood mitochondrial leukoencephalopathy. Neuroradiology 2004;46:267–71

    CrossRefPubMed
14. 14.↵
    1. Duning T,
    2. Deppe M,
    3. Keller S,
    4. et al

    . Diffusion tensor imaging in a case of Kearns-Sayre syndrome: striking brainstem involvement as a possible cause of oculomotor symptoms. J Neurol Sci 2009;281:110–11

    CrossRefPubMed
15. 15.↵
    1. Hirano M,
    2. Ricci E,
    3. Koenigsberger MR,
    4. et al

    . MELAS: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992;2:125–35

    CrossRefPubMed
16. 16.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW,
    4. et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23:S208–19

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Woolrich MW,
    2. Jbabdi S,
    3. Patenaude B,
    4. et al

    . Bayesian analysis of neuroimaging data in FSL. Neuroimage 2009;45:S173–86

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Johansen-Berg H,
    4. et al

    . Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487–505

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Smith SM

    . Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143–55

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Andersson JL,
    2. Jenkinson M,
    3. Smith S

    . Non-linear optimisation. FMRIB Analysis Group Technical Report. TR07JA1. 2007. www.fmrib.ox.ac.uk/analysis/techrep. Accessed April 15, 2010
21. 21.↵
    1. Andersson JL,
    2. Jenkison M,
    3. Smith S

    . Non-linear registration, aka spatial normalisation. FMRIB Analysis Group Technical Report. TR07JA2. 2007. www.fmrib.ox.ac.uk/analysis/techrep. Accessed April 15, 2010
22. 22.↵
    1. Rueckert D,
    2. Sonoda LI,
    3. Hayes C,
    4. et al

    . Non-rigid registration using free-form deformations: application to breast MR imaging. IEEE Trans Med Imaging 1999;18:712–21

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Smith SM,
    2. Zhang Y,
    3. Jenkinson M,
    4. et al

    . Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Jenkinson M,
    2. Smith S

    . A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5:143–56

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Jenkinson M,
    2. Bannister PR,
    3. Brady JM,
    4. et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Zhang Y,
    2. Brady M,
    3. Smith S

    . Segmentation of brain MR images through a hidden Markov random field model and the expectation maximization algorithm. IEEE Trans Med Imaging 2001;20:45–57

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Ashburner J,
    2. Friston K

    . Voxel-based morphometry: the methods. Neuroimage 2000;11:805–21

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Good C,
    2. Johnsrude I,
    3. Ashburner J,
    4. et al

    . A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21–36

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Smith SM,
    2. Nichols TE

    . Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83–98. Epub 2008 Apr 11

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Geurts JJ,
    2. Barkhof F

    . Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841–51

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Castillo M,
    2. Kwock L,
    3. Green C

    . MELAS syndrome: imaging and proton MR spectroscopic findings. AJNR Am J Neuroradiol 1995;15:233–39
32. 32.↵
    1. Apostolova LG,
    2. White M,
    3. Moore SA,
    4. et al

    . Deep white matter pathologic features in watershed regions: a novel pattern of central nervous system involvement in MELAS. Arch Neurol 2005;62:1154–56

    CrossRefPubMed
33. 33.↵
    1. Tsuchiya K,
    2. Miyazaki H,
    3. Akabane H,
    4. et al

    . MELAS with prominent white matter gliosis and atrophy of the cerebellar granular layer: a clinical, genetic, and pathological study. Acta Neuropathol 1999;97:520–24

    CrossRefPubMed
34. 34.↵
    1. Lindroos MM,
    2. Borra RJ,
    3. Parkkola R,
    4. et al

    . Cerebral oxygen and glucose metabolism in patients with mitochondrial m. 3243A>G mutation. Brain 2009;132:3274–84

    Abstract/FREE Full Text
35. 35.↵
    1. Abe K,
    2. Yoshimura H,
    3. Tanaka H,
    4. et al

    . Comparison of conventional and diffusion-weighted MRI and proton MR spectroscopy in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like events. Neuroradiology 2004;46:113–17

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Clark JM,
    2. Marks MP,
    3. Adalsteinsson E,
    4. et al

    . MELAS: clinical and pathologic correlations with MRI, xenon/CT, and MR spectroscopy. Neurology 1996;46:223–27

    Abstract/FREE Full Text
37. 37.↵
    1. Schwartz RB,
    2. Jone KM,
    3. Kalina P,
    4. et al

    . Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992;159:379–83

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Taylor WD,
    2. Payne ME,
    3. Krishnan KR,
    4. et al

    . Evidence of white matter tract disruption in MRI hyperintensities. Biol Psychiatry 2001;50:179–83

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Engelsen BA,
    2. Charalampos T,
    3. Karlsen B,
    4. et al

    . POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008;131:818–28

    Abstract/FREE Full Text
40. 40.↵
    1. Bookstein FL

    . “Voxel-based morphometry” should not be used with imperfectly registered images. Neuroimage 2001;14:1454–62

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Ashburner J,
    2. Friston KJ

    . Why voxel-based morphometry should be used. Neuroimage 2001;14:1238–43

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Henley SM,
    2. Ridgway GR,
    3. Scahill RI,
    4. et al

    . Pitfalls in the use of voxel-based morphometry as a biomarker: examples from Huntington disease. AJNR Am J Neuroradiol 2010;31:711–19

    Abstract/FREE Full Text